Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SHH | Q15465 | 1/20 | 0.42 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553148 | 0.89 | HDAC6 (0.47) | HDAC6TP53MAPT | |
| SCHEMBL13043448 | 0.88 | HPGD (0.48) | MEN1KMT2AALBHTR1ASLC6A2 | |
| SCHEMBL13552781 | 0.88 | USP28 (0.52) | MEN1KMT2AALBHTR1ASLC6A2 | |
| SCHEMBL14707356 | 0.86 | TRPV1 (0.44) | MEN1KMT2ATP53MAPT | |
| SCHEMBL13552821 | 0.86 | LRRK2 (0.48) | HDAC6 | |
| SCHEMBL13552785 | 0.85 | DNMT1 (0.49) | MEN1KMT2A | |
| SCHEMBL13043166 | 0.85 | NPC1 (0.53) | MAPT | |
| SCHEMBL13044592 | 0.84 | CACNA1B (0.48) | MEN1KMT2A | |
| SCHEMBL15502795 | 0.84 | STK39 (0.53) | MEN1KMT2A | |
| SCHEMBL13552818 | 0.84 | HDAC1 (0.47) | HDAC6KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2440048-B1 | ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | MEN1 1016/4885KMT2A 2378/4885CSNK2A1 970/4885 |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | MEN1 1456/4885KMT2A 1798/4885CSNK2A1 1273/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | MEN1 1016/4885KMT2A 2378/4885CSNK2A1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.